Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) confirms New Clinical Trial place for Neuro-Spinal Scaffold

Invivo Therapeutics Holdings Corp(OTCMKTS:NVIV) has confirmed that UC Davis Medical Center in Sacramento, CA will be added as a clinical site in the firm’s ongoing IDE pilot study of the Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI).

The centre is 65,000 square-mile territory covering 33 counties and over 6 million residents in central and northern California.

InVivo’s CEO and Chairman, Mark Perrin, stated that he is glad with the fresh addition to the firm’s present clinical study of the Neuro-Spinal Scaffold. He added that they have ten clinical sites which are open to enrolment of the remaining subjects of pilot trial.

The company had its first enrolment last year in October at Medical Center in Phoenix and AZ Barrow Neurological Institute at St. Joseph’s Hospital.

The firm had announced enrolment of second patient in Carolinas Medical Center in Charlotte, NC in January, 2015.

This is the company’s first clinical study of its investigational degradable polymer Neuro-Spinal Scaffold.

Approved by the U.S. Food and Drug Administration (FDA), the study intends to capture preliminary safety as well as effectiveness data of the Neuro-Spinal Scaffold in five subjects.

The biodegradable Neuro-Spinal Scaffold is surgically implanted at middle of the place where one has got the wound and helps in nerve sprouting.

InVivo Therapeutics Holdings Corp is biomaterials and biotechnology company at research level giving attention to treatment of spinal cord injuries. The firm was founded by Robert Langer, ScD, Professor at Massachusetts Institute of Technology along with Joseph P. Vacanti, MD.

The firm earned David S. Apple Award from the American Spinal Injury Association in 2011 due to superb contribution to spinal cord injury medicine.

Related News

Leave a Reply

Your email address will not be published. Required fields are marked *

Copyrıght 2015 traders350.com. All RIGHTS RESERVED.